Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Artículo en Inglés | MEDLINE | ID: mdl-37351708

RESUMEN

Autistic traits are continuously distributed in the general population. The associations between autistic traits and intellectual functioning and/or behavioural difficulties, and the impact of intellectual functioning on behavioural difficulties are unclear. The study aims to describe the distribution of autistic traits in a population-based cross-sectional sample of children. Further aims are to examine the association between intellectual functioning and autistic traits, and between autistic traits and behavioural difficulties. Wechsler scales and ratings of autistic traits and behavioural problems in 874 children aged 7-9 years in the Swedish Environmental Longitudinal Mother and Child, Asthma and Allergy (SELMA) study were assessed. We found a continuous distribution of autistic traits. Intellectual functioning was negatively associated with autistic traits but not with behavioural difficulties. Behavioural difficulties were associated with autistic traits.

2.
Eur Child Adolesc Psychiatry ; 31(7): 1-13, 2022 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33721085

RESUMEN

Attention-deficit/hyperactivity disorder (ADHD) in adolescence is associated with behavioural, emotional and interpersonal problems, and non-pharmacological treatments targeting these difficulties have been requested. The objective of this study was to evaluate the effectiveness and acceptance of an age-adapted structured skills training group (SSTG) for adolescents with ADHD. Adolescents (n = 184, ages 15-18 years) with a diagnosis of ADHD were randomly assigned to either the SSTG, which is based on dialectical behavioural therapy, or an active control group based on psychoeducation. Symptoms of ADHD, behavioural and emotional problems, functional impairment, and health-related outcomes were assessed with self-ratings and parental ratings two weeks before, two weeks after, and six months after treatment. All participants who completed the pre-treatment measurements (n = 164) were included in the main analyses, which were conducted using a linear mixed model. Our results demonstrated no significant group differences in favour of the SSTG for any of the study outcomes. A majority of the participants in both groups reported that they had increased their knowledge about ADHD, improved their ability to manage problems related to the diagnosis, and would recommend the treatment to others. We conclude that the SSTG seems to be acceptable for adolescents with ADHD in a clinical context. However, the treatment was not proved to be more effective or more acceptable than the psychoeducational control intervention.Trial registration: http://www.isrctn.com/ISRCTN17366720,11/05/2016 , retrospectively registered.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Adolescente , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Humanos , Padres/psicología
3.
Environ Int ; 134: 105185, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31668669

RESUMEN

BACKGROUND: Endocrine disrupting chemicals (EDCs) are xenobiotics with the ability to interfere with hormone action, even at low levels. Prior environmental epidemiology studies link numerous suspected EDCs, including phthalates and bisphenol A (BPA), to adverse neurodevelopmental outcomes. However, results for some chemicals were inconsistent and most assessed one chemical at a time. OBJECTIVES: To evaluate the overall impact of prenatal exposure to an EDC mixture on neurodevelopment in school-aged children, and identify chemicals of concern while accounting for co-exposures. METHODS: Among 718 mother-child pairs from the Swedish Environmental Longitudinal, Mother and child, Asthma and allergy study (SELMA) study, we used Weighted Quantile Sum (WQS) regression to assess the association between 26 EDCs measured in 1st trimester urine or blood, with Wechsler Intelligence Scale for Children (IV) Intelligence Quotient (IQ) scores at age 7 years. Models were adjusted for child sex, gestational age, mother's education, mother's IQ (RAVEN), weight, and smoking status. To evaluate generalizability, we conducted repeated holdout validation, a machine learning technique. RESULTS: Using repeated holdout validation, IQ scores were 1.9-points (CI = -3.6, -0.2) lower among boys for an inter-quartile-range (IQR) change in the WQS index. BPF made the largest contribution to the index with a weight of 14%. Other chemicals of concern and their weights included PBA (9%), TCP (9%), MEP (6%), MBzP (4%), PFOA (6%), PFOS (5%), PFHxS (4%), Triclosan (5%), and BPA (4%). While we did observe an inverse association between EDCs and IQ among all children when training and testing the WQS index estimate on the full dataset, these results were not robust to repeated holdout validation. CONCLUSION: Among boys, early prenatal exposure to EDCs was associated with lower intellectual functioning at age 7. We identified bisphenol F as the primary chemical of concern, suggesting that the BPA replacement compound may not be any safer for children. Future studies are needed to confirm the potential neurotoxicity of replacement analogues.


Asunto(s)
Efectos Tardíos de la Exposición Prenatal , Compuestos de Bencidrilo , Niño , Disruptores Endocrinos , Femenino , Humanos , Pruebas de Inteligencia , Masculino , Madres , Embarazo , Triclosán
4.
J Atten Disord ; 24(2): 246-254, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-30371133

RESUMEN

Objective: The objective of this study was to investigate odds ratios of overweight/obesity in children with ADHD and to compare the change in body mass index (BMI) after initiation of methylphenidate treatment in normal versus overweight/obese children. Method: This population-based study included 724 children (<18 years), of whom 197 were girls. Odds ratios for overweight and obesity were calculated, comparing the study group with a reference group from the same area. After initiation of methylphenidate treatment, changes in BMI were assessed for up to 3 years. Results: Children with ADHD had an odds ratio of 1.87 (95% confidence interval [CI]: [1.60, 2.19]) for overweight/obesity. A decrease in BMI standard deviation score was identified 1 to 3 years into treatment. The decrease was beneficially greater in overweight/obese as compared with normal weight children-mean (SD) -0.64 (0.80) versus -0.39 (0.68); p = .001-and greater in girls. Conclusion: Medication with methylphenidate may facilitate favorable weight development in children with ADHD and overweight/obesity.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Metilfenidato , Obesidad Infantil , Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Índice de Masa Corporal , Niño , Femenino , Humanos , Metilfenidato/uso terapéutico , Sobrepeso/epidemiología , Obesidad Infantil/epidemiología
5.
BMC Psychiatry ; 19(1): 171, 2019 06 10.
Artículo en Inglés | MEDLINE | ID: mdl-31182047

RESUMEN

BACKGROUND: Attention deficit/hyperactivity disorder (ADHD) has a negative impact on several domains of life. However, there is a shortage of evidence-based non-pharmacological treatments for adolescents with ADHD. A structured skills training group (SSTG) based on dialectical behaviour therapy (DBT) has been used in adult patients with ADHD with some promising results, although the treatment has not yet been adapted or evaluated for adolescents with ADHD. This study protocol describes how this treatment was adapted for an adolescent population and how the efficacy of the SSTG will be evaluated using a randomised controlled trial (RCT) design. METHODS: A sample of 184 adolescents (15-18 years of age) with a diagnosis of ADHD has been recruited from seven child and adolescent psychiatric outpatient units and randomised to either the SSTG or an active control group based on psychoeducation. Measures are conducted weekly during the treatment, as well as 2 weeks before treatment and 2 weeks and 6 months after treatment. The primary outcome measures are ADHD symptoms, functional impairment, quality of life and mindfulness. Secondary outcome measures are symptoms of comorbid psychopathology, perceived stress and sleep problems. This article describes the design, methods and analysis plan for evaluating the efficacy of the SSTG. DISCUSSION: The study will be the first RCT to examine the acceptability and efficacy of a SSTG based on DBT adapted for adolescents with ADHD. We believe that the study will extend the current knowledge base about psychological treatment for adolescents with ADHD. TRIAL REGISTRATION: ISRCTN registry ( ISRCTN17366720 ). Retrospectively registered May 112,016.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/terapia , Terapia Conductual Dialéctica/métodos , Adolescente , Trastorno por Déficit de Atención con Hiperactividad/psicología , Femenino , Humanos , Masculino , Atención Plena , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento
7.
J Autism Dev Disord ; 46(7): 2292-304, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26936160

RESUMEN

There has been an increasing interest in possible connections between autism spectrum disorder (ASD) and schizophrenia in the last decade. Neuropsychological comparison studies have, however, been few. The present study examined similarities and differences in intellectual and executive functioning between adults with Asperger syndrome (AS) and adults with schizophrenic psychosis (SP). A group with AS and a group with SP were assessed neuropsychologically with WAIS-III and D-KEFS. Similarities were found between groups, as displayed by an uneven cognitive profile, limitations in working memory, processing speed and some aspects of executive functioning. Full Scale IQ was higher in the AS group. These results add to the current research illuminating similarities and differences between ASD and schizophrenia on a cognitive level.


Asunto(s)
Síndrome de Asperger/psicología , Función Ejecutiva/fisiología , Memoria a Corto Plazo/fisiología , Trastornos Psicóticos/psicología , Psicología del Esquizofrénico , Adulto , Trastorno del Espectro Autista/psicología , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas , Adulto Joven
9.
Eur J Clin Pharmacol ; 71(7): 877-81, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25995170

RESUMEN

PURPOSE: The use of melatonin is increasing among Swedish children and adolescents despite deficient knowledge of usage in these groups. The aim of this study was to investigate the use of melatonin in Swedish children and adolescents according to age, gender, dosage, treatment duration, and use of attention deficit hyperactivity disorder (ADHD) medication. METHODS: Data from the Swedish Prescribed Drug Register was analyzed for children and adolescents 0-19 years old in Sweden during 2006-2013. RESULTS: The number of new users of melatonin in 2013 was 4296 and 3093 among boys and girls, respectively. Girls started treatment with melatonin in older ages compared to boys. Regular users of melatonin were most common among boys 10-14 years. The average defined daily dose (DDD) per regular user was decreasing from 2.4 DDD in 2006 to 1.7 DDD in 2012. Among girls and boys 5-9 years who were regular users in 2010, over 40 and 50%, respectively, were still regular users in 2013. In the age group 15-19 years, only about 10% were still regular users in 2013. In 2013, 65% of boys and 49% of girls, using melatonin regularly, also used medication for ADHD regularly. CONCLUSIONS: More Swedish boys than girls used melatonin regularly. The boys started treatment earlier and more often combined regular use of melatonin with regular use of medication for ADHD. This indicates that girls and boys partly are prescribed melatonin for different reasons. About half of the younger children stayed on melatonin treatment for several years, while 90% of adolescents (15-19 years) concluded their treatment.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Depresores del Sistema Nervioso Central/administración & dosificación , Estimulantes del Sistema Nervioso Central/uso terapéutico , Melatonina/administración & dosificación , Pautas de la Práctica en Medicina/tendencias , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Sueño/efectos de los fármacos , Adolescente , Conducta del Adolescente/efectos de los fármacos , Factores de Edad , Trastorno por Déficit de Atención con Hiperactividad/complicaciones , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Trastorno por Déficit de Atención con Hiperactividad/psicología , Depresores del Sistema Nervioso Central/efectos adversos , Estimulantes del Sistema Nervioso Central/efectos adversos , Niño , Conducta Infantil/efectos de los fármacos , Preescolar , Esquema de Medicación , Quimioterapia Combinada , Revisión de la Utilización de Medicamentos , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Melatonina/efectos adversos , Sistema de Registros , Factores de Riesgo , Factores Sexuales , Trastornos del Sueño-Vigilia/diagnóstico , Trastornos del Sueño-Vigilia/etiología , Trastornos del Sueño-Vigilia/fisiopatología , Suecia , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
10.
Nord J Psychiatry ; 69(4): 268-74, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25389915

RESUMEN

BACKGROUND: In clinical practice, the differential diagnosis of Asperger syndrome (AS) versus schizophrenia can be a challenge. Some self-report instruments-such as the Autism-spectrum Quotient (AQ)-have been portrayed as proxies for the diagnosis of AS. However, it has not been demonstrated to what extent autistic traits-as measured by the AQ-separate AS from schizophrenia. AIM: To examine the AS-schizophrenia discriminating ability of the AQ. METHOD: The AQ is a 50-item self-administered questionnaire (with score range 0-50) for measuring "autistic traits" in adults. Here, it was completed by 136 individuals: 36 with schizophrenic psychosis, 51 with AS and 49 non-clinical comparison cases. A receiver operating characteristic (ROC) analysis for the total AQ score was performed to examine the discriminating power of the instrument. RESULT: Both individuals with schizophrenia and individuals with AS scored significantly higher on AQ than the non-clinical group. The mean total AQ score (± standard deviation) of the AS group (26.7 ± 8.9; range 9-44) was significantly higher than that of the schizophrenia group (22.7 ± 6.2; range 10-35) (P = 0.041). However, when using the full Likert scale for scoring, the difference did not reach significance. In the ROC analysis of total AQ scores for AS versus schizophrenia, the area under the curve (AUC) was 0.65 (P = 0.02). CONCLUSION: Although mean AQ scores separated AS and schizophrenia at a group comparison level, significant overlap of AQ scores across the two diagnostic groups clearly reduces the discriminating power of the AQ in the separation of schizophrenia from AS.


Asunto(s)
Síndrome de Asperger/diagnóstico , Trastorno Autístico/diagnóstico , Esquizofrenia/diagnóstico , Psicología del Esquizofrénico , Autoinforme/estadística & datos numéricos , Autoinforme/normas , Adulto , Síndrome de Asperger/psicología , Trastorno Autístico/psicología , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Encuestas y Cuestionarios , Adulto Joven
11.
J Atten Disord ; 18(5): 425-33, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22498753

RESUMEN

OBJECTIVE: To examine ADHD prevalence, rating scales, and relationship to nicotine use in adults with schizophrenia or Asperger syndrome. METHOD: Ninety-five individuals, 41 with schizophrenia and 54 with Asperger syndrome, were included. Self-rating of adult ADHD symptoms with the Wender-Reimherr Adult Attention Deficit Diagnostic Rating Scale (WRAADDS), parent rating of proband's ADHD childhood and adult life symptoms using the Swanson, Nolan, and Pelham Questionnaire (SNAP), and report of clinical ADHD diagnosis were included as ADHD measures. Nicotine use data were compared with data from a population sample. RESULTS: In all, 10% of the schizophrenia group and 30% of the Asperger syndrome group had a clinical ADHD diagnosis. Nicotine dependency in the whole sample was closely linked to ADHD. CONCLUSION: The prevalence of comorbid ADHD was high in schizophrenia and Asperger syndrome. The WRAADDS self-rating scale for ADHD can be one useful tool for assessing comorbid ADHD in these patient groups.


Asunto(s)
Síndrome de Asperger/epidemiología , Nicotina/efectos adversos , Esquizofrenia/epidemiología , Tabaquismo/epidemiología , Adulto , Síndrome de Asperger/diagnóstico , Síndrome de Asperger/psicología , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Trastorno por Déficit de Atención con Hiperactividad/psicología , Comorbilidad , Femenino , Humanos , Masculino , Prevalencia , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Esquizofrenia/diagnóstico , Encuestas y Cuestionarios , Tabaquismo/diagnóstico , Tabaquismo/psicología
12.
Compr Psychiatry ; 53(4): 333-40, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-21821235

RESUMEN

BACKGROUND: The relationship between autism spectrum disorders/pervasive developmental disorders and personality disorders is not completely clear, although both concepts imply lifelong impairment. The purpose of the present study was to investigate the presence of possible personality disorders in a group of young adults with Asperger syndrome. METHOD: Fifty-four young adults with a clinical diagnosis of Asperger syndrome were assessed with Structured Clinical Interview for DSM-IV Axis II disorders to evaluate the presence of a concomitant personality disorder and completed the Autism Spectrum Quotient to measure level of autistic features. Autism spectrum diagnosis was confirmed by Diagnostic Interview for Social and Communication Disorders with a collateral informant. RESULTS: Approximately half of the study group fulfilled criteria for a personality disorder, all belonging to cluster A or C. There was a significant difference across sex: men with Asperger syndrome meeting personality disorder criteria much more often than women with Asperger syndrome (65% vs 32%). Participants fulfilling criteria for a personality disorder showed more marked autistic features according to the Autism Spectrum Quotient. CONCLUSIONS: There is a considerable overlap in symptoms between Asperger syndrome and certain personality disorders. Similarities and differences of the two concepts are discussed in the framework of the Diagnostic and Statistical Manual of Mental Disorders classification system.


Asunto(s)
Síndrome de Asperger/complicaciones , Trastornos de la Personalidad/complicaciones , Adulto , Síndrome de Asperger/diagnóstico , Femenino , Humanos , Masculino , Determinación de la Personalidad , Trastornos de la Personalidad/diagnóstico , Escalas de Valoración Psiquiátrica , Psicometría , Factores Sexuales
13.
Res Dev Disabil ; 32(5): 1910-7, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21515028

RESUMEN

In children with autism spectrum disorders, previous studies have shown high rates of psychiatric comorbidity. To date, studies on adults have been scarce. The aim of the present study was to investigate psychiatric comorbidity in young adults with Asperger syndrome. Participants were 26 men and 28 women (mean age 27 years) with a clinical diagnosis of Asperger syndrome. Psychiatric comorbidity was assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders. IQ was measured using the Wechsler Adult Intelligence Scale, Third Edition. Autism spectrum diagnoses were confirmed using the DIagnostic Interview for Social and Communication Disorders. In our study group, 70% had experienced at least one episode of major depression, and 50% had suffered from recurrent depressive episodes. Anxiety disorders were seen in about 50%. Psychotic disorders and substance-induced disorders were uncommon. In conclusion, young adults with autism spectrum disorders are at high risk for mood and anxiety disorders. To identify these conditions and offer treatment, elevated vigilance is needed in clinical practice.


Asunto(s)
Síndrome de Asperger/epidemiología , Síndrome de Asperger/psicología , Trastornos Mentales/epidemiología , Adulto , Trastornos de Ansiedad/epidemiología , Comorbilidad , Trastorno Depresivo/epidemiología , Femenino , Humanos , Masculino , Trastornos del Humor/epidemiología , Trastornos Psicóticos/epidemiología , Factores de Riesgo , Distribución por Sexo , Trastornos Relacionados con Sustancias/epidemiología , Adulto Joven
14.
Cogn Neuropsychiatry ; 14(2): 127-43, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19370436

RESUMEN

INTRODUCTION: The Reading the Mind in the Eyes Test is a widely used facial affect recognition test. The present study aimed to provide Swedish nonpatient reference values, examine test-retest reliability, and to elucidate strengths and weaknesses of the instrument. METHODS: A Swedish version of the test was completed by 158 university students. Fifty-eight participants completed the test twice, 3 weeks apart. The Bland Altman method was used to examine the test-retest reliability. RESULTS: Distribution of responses of the 158 participants is detailed and compared with the English version. The limits of agreement was +/-4.3. CONCLUSIONS: A test score variation in the range of +/-4 (out of 24 possible) is to be expected for the same individual. When the Reading the Mind in the Eyes Test is used, one has to take into account that an obtained test score must be regarded as an approximation.


Asunto(s)
Afecto/fisiología , Expresión Facial , Pruebas Psicológicas , Reconocimiento en Psicología/fisiología , Adulto , Interpretación Estadística de Datos , Femenino , Humanos , Lenguaje , Masculino , Reproducibilidad de los Resultados , Caracteres Sexuales , Suecia , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...